Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitisinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD known ✓ | P32754 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitisinone SCHEMBL29372670 | 1.00 | HPD (1.00) | HPDFLT1FLT4KDRMAPT | |
| Nitisinone SCHEMBL15537279 | 1.00 | HPD (1.00) | HPDFLT1FLT4KDRMAPT | |
| SCHEMBL15996621 | 0.88 | HPD (0.79) | HPDMAPTMAPK1MEN1KMT2A | |
| Nitisinone SCHEMBL8423048 | 0.87 | HPD (0.75) | HPDFLT1FLT4KDRMAPK1 | |
| SCHEMBL9132899 | 0.86 | HPD (0.76) | HPDFLT1FLT4KDRMAPT | |
| SCHEMBL29000080 | 0.85 | HPD (0.74) | HPDFLT1FLT4KDRMAPT | |
| SCHEMBL9137621 | 0.85 | HPD (0.74) | HPDFLT1FLT4KDRMAPT | |
| SCHEMBL9711453 | 0.84 | HPD (0.73) | HPDFLT1FLT4KDRMAPT | |
| SCHEMBL9133822 | 0.83 | HPD (0.70) | HPDFLT1FLT4KDRMAPT | |
| SCHEMBL10405322 | 0.81 | HPD (0.67) | HPDFLT1FLT4KDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124161-A1 | NITISINONE ADMINISTRATION TO LIVESTOCK FOR HEMATOPHAGOUS ARTHROPOD CONTROL | UNIV NEBRASKA (US) | 2026-05-07 | — | — | US | claimed |
| EP-4593590-A1 | CORRECTION OF HEPATOSTEATOSIS IN HUMANIZED LIVER ANIMALS THROUGH RESTORATION OF IL6/IL6R/GP130 SIGNALING IN HUMAN HEPATOCYTES | Regeneron Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025088004-A1 | PAEDIATRIC FORMULATIONS FOR PHENYLKETONURIA AND TYROSINAEMIA AND SPECIFIC FREE AMINO ACID MIXTURE | Société des Produits Nestlé S.A. (CH) | 2025-05-01 | — | — | WO | claimed |
| US-20250134019-A1 | TRIKETONE DIOXYGENASE VARIANTS FOR HERBICIDE TOLERANCE | MONSANTO TECHNOLOGY LLC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250009808-A1 | Methods of Producing and Using Human Hepatocytes and Related Compositions | CYTOTHERYX INC (US) | 2025-01-09 | — | — | US | claimed |
| US-20240398819-A1 | UTILITY OF VITAMIN D, FOLIC ACID AND NADH TO IMPROVE LIGAMENT INJURY PREVENTION CHARACTERISTICS | RHODE ISLAND HOSPITAL | 2024-12-05 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240344072-A1 | TREATMENT FOR TYROSINE DEGRADATION-ASSOCIATED DISORDERS | UCL BUSINESS LTD (GB) | 2024-10-17 | — | — | US | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2007100905-A2 | ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION | NEXGEN THERAPEUTICS, LLC (US) | 2007-09-07 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2006090177-A1 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE | SYNGENTA LIMITED (GB) | 2006-08-31 | — | — | WO | claimed |
| EP-0591275-B1 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE IN THE TREATMENT OF TYROSINAEMIA AND PHARMACEUTICAL COMPOSITIONS | ZENECA LTD (GB) | 1999-03-31 | — | — | EP | claimed |
| US-5668089-A | 2-(2'-NITRO-4'-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE | ZENECA LIMITED (GB) | 1997-09-16 | — | — | US | claimed |
| US-5550165-A | CONTAINING 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITING AMOUNT OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE | ZENECA LIMITED (GB) | 1996-08-27 | — | — | US | claimed |
| EP-0591275-A1 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE IN THE TREATMENT OF TYROSINAEMIA AND PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000080-A1 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE IN THE TREATMENT OF TYROSINAEMIA AND PHARMACEUTICAL COMPOSITIONS | ZENECA LTD. (GB) | 1993-01-07 | — | — | WO | claimed |
| US-4774360-A | Converting enol ester precursor of a benzoyl-1,3-cycloalkyldione to a benzoyl-1,3-cycloalkyldione | STAUFFER CHEMICAL COMPANY (US) | 1988-09-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124161-A1 | NITISINONE ADMINISTRATION TO LIVESTOCK FOR HEMATOPHAGOUS ARTHROPOD CONTROL | TH, CYP2E1, COX15 | HPD 93/4885FLT1 937/4885FLT4 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.